Literature DB >> 31203490

Rational creation and systematic analysis of cervical cancer kinase-inhibitor binding profile.

Min Han1, Dongdong Sun2.   

Abstract

The kinase-regulatory cell signaling networks play a central role in the pathogenesis of human cervical cancer (hCC). However, only few kinase inhibitors have been successfully developed for treatment of this cancer to date. Considering that the active sites of protein kinases are highly conserved and small-molecule inhibitors should generally exhibit high promiscuity and broad specificity across the hCC-related kinase array, it is supposed that the established kinase targets of hCC can be targeted unexpectedly by certain noncognate kinase inhibitors. This provides a novel idea to practice the new uses for old drugs in anti-cancer chemotherapy. Here, we create a systematic kinase-inhibitor binding profile in a high-throughput manner by molecular docking and consensus scoring, where the kinases have been collected as therapeutic targets of hCC and the inhibitors are reversible, ATP-competitive and readily available. The docking/scoring scheme is tested rigorously with structure-solved and affinity-known kinase-inhibitor complex samples, which is later demonstrated to be effective in inferring unexpected inhibitor response to hCC-related kinases. Few promising kinase-inhibitor pairs are identified from the profile and tested experimentally at cellular and molecular levels. It is found that the kinase-inhibitor promiscuity is a common phenomenon but only few can interaction effectively and inhibit potently. In addition, the high-scoring inhibitors generally exhibit good suppressing potency on hCC cell viability as compared to those low-scoring ones, imparting that the created profile can well reflect the tumor cytotoxicity of noncognate kinase inhibitors. A further kinase assay suggests that the ErbB family kinases are the potential targets of these high-scoring inhibitors, with noncognate inhibitory activity up to nanomolar level. Structure analysis reveals that the nonbonded interactions of potent noncogante kinase-inhibitor binding can divided into a polar tail and a nonpolar lobe, which confer specificity and stability to the binding, respectively.

Entities:  

Keywords:  Cell viability; Cervical cancer; Consensus scoring; Inhibitory activity; Kinase–inhibitor binding profile; Molecular docking

Year:  2019        PMID: 31203490     DOI: 10.1007/s10822-019-00211-1

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  48 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Gene ontology: tool for the unification of biology. The Gene Ontology Consortium.

Authors:  M Ashburner; C A Ball; J A Blake; D Botstein; H Butler; J M Cherry; A P Davis; K Dolinski; S S Dwight; J T Eppig; M A Harris; D P Hill; L Issel-Tarver; A Kasarskis; S Lewis; J C Matese; J E Richardson; M Ringwald; G M Rubin; G Sherlock
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

Review 3.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

4.  Comparative evaluation of 11 scoring functions for molecular docking.

Authors:  Renxiao Wang; Yipin Lu; Shaomeng Wang
Journal:  J Med Chem       Date:  2003-06-05       Impact factor: 7.446

5.  The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures.

Authors:  Renxiao Wang; Xueliang Fang; Yipin Lu; Shaomeng Wang
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

6.  Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.

Authors:  Christopher M Lee; Christa B Fuhrman; Vicente Planelles; Morgan R Peltier; David K Gaffney; Andrew P Soisson; Mark K Dodson; H Dennis Tolley; Christopher L Green; Karen A Zempolich
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

7.  Consensus scoring criteria for improving enrichment in virtual screening.

Authors:  Jinn-Moon Yang; Yen-Fu Chen; Tsai-Wei Shen; Bruce S Kristal; D Frank Hsu
Journal:  J Chem Inf Model       Date:  2005 Jul-Aug       Impact factor: 4.956

8.  New uses for old drugs.

Authors:  Curtis R Chong; David J Sullivan
Journal:  Nature       Date:  2007-08-09       Impact factor: 49.962

9.  Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.

Authors:  Mayumi Ono; Akira Hirata; Takuro Kometani; Miho Miyagawa; Shu-ichi Ueda; Hisafumi Kinoshita; Teruhiko Fujii; Michihiko Kuwano
Journal:  Mol Cancer Ther       Date:  2004-04       Impact factor: 6.261

Review 10.  Protein kinases, their function and implication in cancer and other diseases.

Authors:  I Shchemelinin; L Sefc; E Necas
Journal:  Folia Biol (Praha)       Date:  2006       Impact factor: 0.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.